Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251847 | 0.85 | OPRM1 (0.51) | OPRM1PTGIRACHE | |
| SCHEMBL3635699 | 0.84 | OPRM1 (0.49) | OPRM1PTGIRACHE | |
| Hydrochloric Acid SCHEMBL3639509 | 0.84 | OPRM1 (0.50) | OPRM1PTGIR | |
| SCHEMBL13930628 | 0.82 | OPRM1 (0.52) | OPRM1DRD2DRD4ACHE | |
| SCHEMBL13930608 | 0.81 | EPHX2 (0.56) | OPRM1CARM1PRMT6 | |
| SCHEMBL13930609 | 0.81 | EPHX2 (0.57) | OPRM1 | |
| SCHEMBL13930636 | 0.81 | NPSR1 (0.56) | — | |
| SCHEMBL3639722 | 0.80 | OPRM1 (0.52) | OPRM1DRD2DRD4ACHE | |
| SCHEMBL13930626 | 0.80 | OPRM1 (0.52) | OPRM1ACHE | |
| SCHEMBL13930669 | 0.80 | NPC1 (0.57) | OPRM1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164491-A1 | PIPERIDINE-4-ACETIC ACID DERIVATIVES AND THEIR USE | Euroscreen S.A. (BE) | 2010-03-24 | — | — | EP | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009010477-A1 | PIPERIDINE-4-ACETIC ACID DERIVATIVES AND THEIR USE | EUROSCREEN S.A. (BE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010479-A2 | HETEROCYCLIC METHYLENE PIPERIDINE DERIVATIVES AND THEIR USE | EUROSCREEN S.A. (BE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010479-A2 | HETEROCYCLIC METHYLENE PIPERIDINE DERIVATIVES AND THEIR USE | EUROSCREEN S.A. (BE) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | LTA4H 553/4885OPRM1 202/4885DRD2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.